Smithkline Beecham Corporation

Glaxo Wellcome Inc.

Glaxosmithkline LLC

Affymax, Inc.

David J Duffin

Steven E Cwirla

William J Dower

Ronald W Barrett

Peter J Schatz

Christopher R Wagstrom

Nicholas C Wrighton

Larry C Mattheakis

Christian M Gates

Sherril S Haselden

Palani Balu

Sunila Piplani

Barbara McEowen Merrill

Sherril S Johnson

Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.

Peptides and compounds that bind to a receptor

Novel compounds are provided that bind to G-CSFR. The novel compounds have a peptide chain approximately 6 to 40 amino acids in length that binds to G-CSFR. The compounds are useful as probes for affinity screening. In addition, the compounds have demonstrated agonist or antagonist activity for the G-CSFR, and are therefore useful in treatment of diseases including patients who suffer from a low white blood cell titer. Pharmaceutical compositions and methods of use are provided as well.

Compounds having affinity for the granulocyte-colony stimulating factor receptor (G-CSFR) and associated uses

Receptors are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.

Peptides and compounds that bind to a thrombopoietin receptor

Peptides and compounds that bind to the thrombopoietin receptor

Growing community of inventors

East Palo Alto, CA, United States of America

David J Duffin